Taysha Gene Therapies Inc. (TSHA)
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TSHA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.21B
- EPS (TTM)
- -$0.42
- Dividend yield
- None
- 52-week range
- 3.46 – 7.30
- Day range
- 3.60 – 3.80
- Volume / Avg
- 3.15M / 3.59M
- Beta
- —
- Shares outstanding
- 326.05M
52-week range
TSHA stock today
Taysha Gene Therapies (TSHA) closed at $3.72 on Nov 20, down 1.33% (-$0.05), versus the S&P 500's 3.70% decline. At this level, TSHA sits near the bottom of its 52-week range of $3.46 to $7.30: 49.0% below the high, set on May 6, 2026 and 7.7% above the low. TSHA is down 32.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 11.2%.
Taysha Gene Therapies has posted a net loss over the last twelve months (EPS of -$0.42), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Taysha Gene Therapies
Company profileTaysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Sean P. Nolan
- Headquarters
- Dallas, TX
- Employees
- 99
- IPO year
- 2020
- Website
- tayshagtx.com
Financial highlights
Full financialsIn fiscal 2025, Taysha Gene Therapies generated $9.8 million in revenue, up 17.3% from fiscal 2024. Taysha Gene Therapies reported a net loss of $109.0 million, compared with a loss of $89.3 million a year earlier. Operating margin was -1130.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $9.77M | $8.33M | $15.45M | $2.50M | — |
| Growth | +17.28% | -46.07% | +517.55% | — | — |
| Net income | $-109.00M | $-89.30M | $-111.57M | $-166.01M | $-174.52M |
| EPS (diluted) | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$13.00+249.46%
- Strong buy 3
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.10 vs $-0.14
- Surprise
- +28.57%
TSHA news
All TSHA news- Taysha Q3 Loss Widens On Higher Expenses; REVEAL 6-Month Interim Data Due In H1'27NasdaqTSHA, LEN.B
- Taysha (TSHA) Q3 2026 Earnings Call TranscriptNasdaq
- Taysha Gene Therapies, Inc. Reports Third Quarter 2026 Financial Results and Corporate UpdateNasdaqTSHA, BF.A
- Taysha Gene Therapies GAAP EPS of -$0.10 beats by $0.03Seeking Alpha
- Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- Taysha Gene Therapies Q3 2026 Earnings PreviewSeeking Alpha
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
Taysha Gene Therapies peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NVAXNovavax Inc. | 7.47 | -3.24% | $1.23B | vs TSHA |
| VORVor Biopharma Inc. | 19.19 | +3.62% | $1.18B | vs TSHA |
| IMCRImmunocore Holdings plc ADR | 26.41 | -0.83% | $1.36B | vs TSHA |
| MESOMesoblast Limited ADR | 10.89 | -2.59% | $1.41B | vs TSHA |
| INBXInhibrx Biosciences Inc. | 68.97 | -7.21% | $1.02B | vs TSHA |
| WWBWindward Bio Group AG | 24.29 | +1.15% | $1.45B | vs TSHA |
| ALVOAlvotech | 4.12 | -3.96% | $1.47B | vs TSHA |
| RXRXRecursion Pharmaceuticals Inc. Class A | 2.45 | -9.93% | $1.53B | vs TSHA |
Indexes, lists and sector
Taysha Gene Therapies stock FAQ
What is Taysha Gene Therapies's stock price today?
TSHA last traded at $3.72 as of Nov 20, 4:00 PM EST, down 1.33% on the day. Prices are delayed at least 15 minutes.
Who is Taysha Gene Therapies's CEO?
Mr. Sean P. Nolan is the chief executive officer of Taysha Gene Therapies Inc., which has about 99 employees.
What is the TSHA 52-week high?
The 52-week high for TSHA is $7.30 and the 52-week low is $3.46. The stock is currently 49.0% below its high.